Cancer Centers in the News

The following links highlight some of the most up-to-date news from the 26 NCCN Member Institutions. The media coverage below includes major national news outlets, industry magazines, medical journals, and press releases.

The news is listed in reverse chronological order for ease of use.

April 6, 2015
NCCN Foundation® Awards Grants to Six Young Investigators

The NCCN Foundation® has awarded its fifth series of Young Investigator Awards to six oncology researchers from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care. 

FORT WASHINGTON, PA — The NCCN Foundation®, which, through philanthropy empowers people through knowledge and advances the mission of the National Comprehensive Cancer Network® (NCCN®) to improve the quality, effectiveness, and efficiency of care provided to people with cancer, has awarded grants to six young investigators from NCCN Member Institutions.

These awardees, who are dedicated to advancing and discovering new treatments for cancer, enhancing quality, and improving patient education, represent the fifth series of the NCCN Foundation Young Investigator Awards—a program initiated in 2011. The grants will provide $150,000 in funding over a two-year period, beginning in July 2015.

“The NCCN Foundation is proud to foster the development of six promising oncology investigators,” said Gary J. Weyhmuller, Executive Vice President and Chief Operating Officer, NCCN. “The support of the NCCN Foundation Young Investigator Awards will indeed provide the opportunity for these young researchers to further high-quality research and improve the lives of people with cancer.”

Following are the 2015 NCCN Foundation Young Investigator Awards recipients:

The awardees responded to a Request for Proposal (RFP) issued by the NCCN Foundation to the NCCN Member Institutions. All submissions were reviewed by a multidisciplinary panel of oncology experts, and the awardees were selected based on several key components, including scientific merit and study design. The studies will be managed and overseen by the NCCN Oncology Research Program (ORP).

Since their inception in 2011, NCCN Foundation Young Investigator Awards have been received by 24 individuals. In March 2015, NCCN featured abstracts highlighting the work of the third series of Young Investigator Awards at the NCCN General Poster Sessions during the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™.

The 2015 NCCN Foundation Young Investigator Awards were made possible through support from AbbVie, Amgen, Genentech, Gilead, Merck, Millennium, Pfizer, and Sigma-Tau.

For more information about the NCCN Foundation Young Investigator Awards, visit NCCN.org.

###

>View Article<



April 2, 2015
Final Roundtable of the NCCN 20th Annual Conference Explores Essential Characteristics of Clinical Practice Recommendations

The third and final roundtable of the NCCN 20th Annual Conference explored essential elements of clinical practice guidelines, as well as the historical development of the NCCN Guidelines®

FORT WASHINGTON, PA — The third and final roundtable of the National Comprehensive Cancer Network® (NCCN®) 20th Annual Conference: Advancing the Standard of Cancer Care™, What are the Characteristics of an Optimal Clinical Practice Guideline?, was held Saturday, March 14, 2015.

Moderated by F. Marc Stewart, MD, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, the following panelists discussed the fundamentals of optimal clinical practice guidelines, as well as lessons learned throughout two decades of development of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and explored the optimal formula for publishing the treatment recommendations that allow for appropriate evidence-based choices in patient management: David S. Ettinger, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Michael Kuettel, MD, PhD, MBA, Roswell Park Cancer Institute; Jennifer Malin, MD, Wellpoint/Anthem; Joan S. McClure, MS, NCCN; Mary Lou Smith, JD, MBA, Research Advocacy Network; and Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center.

Dr. Stewart commenced the roundtable discussion by asking how the NCCN Guidelines® have changed since their initial publication in 1996.

Ms. McClure, Senior Vice President for Clinical Information and Publications, NCCN, discussed that one of the major changes to the Guidelines in the past two decades is that they have become more complex for two reasons—first, they have been built out from their original, shorter format; and, second, the treatment of cancer has also increased in complexity. Indeed, noted Ms. McClure, one major advancement was the availability of the NCCN Guidelines online in real-time, as opposed to printed copies that were available originally.

Dr. Ettinger, who has chaired the NCCN Guidelines Panel for Non-Small Cell Lung Cancer (NSCLC) since its inception, noted that one constant of the NCCN Guidelines development process is that it has been funded, since day one, solely by membership dues and noted the comparable growth of the Guidelines panels to the NCCN Guidelines themselves.

"The Lung Cancer Guidelines Panel, in 1996, had seven members...now we have 35 panel members. In ’96, we had 40 references. The present Guidelines have 718 references," said Dr. Ettinger.

Fellow panelists noted the considerable increase in data and evidence included in the Guidelines since they were published in 1996.

Regarding the advancements of the NCCN Guidelines panels since 1996, Ms. Smith,  who was the first patient advocate to sit on an NCCN Guidelines Panel noted that, today, there are advocates representing the patient voice and patient concerns on many of the panels.

“We have come a long way,” she said.

For patients, the most important change to the NCCN Guidelines over the past 20 years was the publication of the NCCN Guidelines for Patients®, said Ms. Smith. The NCCN Guidelines for Patients take the complex information of the Guidelines and make it more understandable for the patients; it’s important to have this information, she said, as the information contained within the NCCN Guidelines gives patients a certainty about the decisions they are making about their treatment.

Dr. Malin expounded, describing how the use of the NCCN Guidelines and their patient-friendly equivalent, allow her to reassure patients that there is a consensus about the treatment they receive in her clinic and that the treatment will indeed follow best-in-class cancer care protocol.

The panel discussed the importance of clinical judgment in the development of the NCCN Guidelines, citing that this has been a deciding factor in treatment recommendations since 1996.

“We started with a rigorous methodology, but it’s evidence-based plus consensus-based,” explained Dr. Ettinger. The better the data, the better the doctor can make the decision about the best therapies to use; sometimes, however, physicians need to think outside the box and use clinical judgment on how to best apply the evidence and the Guidelines to a particular patient, he explained.

Dr. Zelenetz, who has chaired NCCN Guidelines panels for various hematologic malignancies, including Non-Hodgkin’s Lymphomas, elaborated, explaining that in many cases—especially hematologic malignancies—a multitude of diagnoses are “orphan” diseases, and there will never be enough high-level evidence to provide high-level meta-analysis. Even in the most common cancers, he added, there are points in treatment in which there is no high-level evidence.

“To ignore areas where we don’t have high-level evidence does a disservice to Guidelines users—the oncologists and patients—because it denies them access to what is expert care at these nodal points where high-level data may not exist,” said Dr. Zelenetz.

Quality of data and systematic review of evidence is crucial to the credibility of the NCCN Guidelines, said the panel.

Dr. Kuettel reviewed the Institute of Medicine (IOM) Recommendations for Developing Trustworthy Clinical Practice Guidelines, noting that the transparent development, multidisciplinary development committees, evidence levels, and review of the NCCN Guidelines indeed fall within the IOM recommended standards.

Dr. Stewart then asked the panel to discuss pathways, which have more selective treatment options among the wide range of recommendations that may be present in the NCCN Guidelines for a particular disease.

The panel discussed Guidelines versus pathways, noting key differences including the consideration of cost, which is a fundamental distinction between the two decision tools.

According to Dr. Zelenetz, pathways can potentially be helpful decision-making tools; however, he noted that this is dependent on the quality of data present, as well as their transparency.

Today, oncology pathways are mainly focused on medical oncology, explained Dr. Kuettel. He noted that an all-inclusive pathway that comprises medical, radiation, and surgical oncology would be optimal in increasing quality and decreasing cost in the treatment of people with cancer.

Considering quality and value with pathways, Ms. Smith noted the need for exceptions. Two patients can be given the same options and make different choices as a result of their preferences, experiences, and values, she explained

Dr. Stewart and the panelists then turned to the future of NCCN Guidelines discussing how the current digitization of the library will enhance the ability to integrate the Guidelines recommendations into electronic health records (EHRs) and decision-support tools, such as IBM Watson

Another major development in the NCCN Guidelines is the further identification and sub-typing of malignancies, based on biology and biomarkers, explained Dr. Zelenetz. He noted the importance of data within the realm of targeted therapies, explaining that when there is a strong parallel between a biomarker and biology, small data sets can be useful.

Finally, Dr. Stewart reviewed the idea of value with the panel members, discussing the new evidence blocks that are projected to be published within the NCCN Guidelines this year, which take into account five variables for value: efficacy, safety, quality of evidence, consistency of evidence, and affordability.

 

These evidence blocks allow for more personalized treatment, accounting for the driving concerns for patients, said Ms. McClure. With this information at the physicians’ fingertips, she explained, they are easily able to discuss with patients the relative merits and drawbacks of therapy options.

For more information about the NCCN Guidelines, visit NCCN.org.

###

>View Article<



March 16, 2015
New NCCN Member Institution: Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute has been named the newest NCCN Member Institution; NCCN now has 26 Member Institutions serving patients throughout the United States.

FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®), an alliance of the world’s leading cancer centers dedicated to quality, effectiveness, and efficiency of cancer care so that patients can live better lives, today announced that Case Comprehensive Cancer Center which includes University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute has been elected to institutional membership. NCCN now has 26 Member Institutions serving patients throughout the United States.

“Case Comprehensive Cancer Center brings to NCCN unique and valuable attributes, including a robust genomics program and clinical research operational infrastructure, that indeed will enhance the already extraordinary collaboration of the alliance,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “We look forward to working with their renowned experts and leadership to further the NCCN mission, support and enhance evidence-based decision-making, and promote the importance of continuous process improvement.”

“I am excited to welcome Case Comprehensive Cancer Center to the NCCN alliance,” said Samuel M. Silver, MD, PhD, University of Michigan Comprehensive Cancer Center, Chair, NCCN Board of Directors. “Collaborating with their expert clinicians and researchers will indeed strengthen our network and improve the lives of patients with cancer.”

Case Comprehensive Cancer Center is an NCI-designated Comprehensive Cancer Center located at Case Western Reserve University. The center, which has been continuously funded since 1987, integrates the cancer research activities of the largest biomedical research and health care institutions in Ohio – Case Western Reserve, University Hospitals (UH) Case Medical Center and the Cleveland Clinic. NCI-designated cancer centers are characterized by scientific excellence and the capability to integrate a diversity of research approaches to focus on the problem of cancer. It is led by Stanton Gerson, MD, Asa and Patricia Shiverick-Jane Shiverick (Tripp) Professor of Hematological Oncology, and also Director of the National Center for Regenerative Medicine, Case Western Reserve, and Director of the Seidman Cancer Center at UH Case Medical Center.

“Our centers join an elite set of nationally recognized cancer centers that set the standards for exceptional cancer care, coordinated cancer services, and top-of-mind guidelines for patient management.  We bring to the network well known national leaders in cancer care, clinical investigation, and translational research, and two highly ranked institutions for cancer care, Seidman Cancer Center and Taussig Cancer Institute, that will add to the capabilities and impact of NCCN. This is a group we are honored to join,” said Dr. Gerson.

Now in its 20th year of operation, originally announced as an alliance of 13 leading cancer centers in 1995, NCCN is devoted to patient care, research, and education in order to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are considered the standard of care and clinical policy by oncologists and payers. The most comprehensive clinical treatment guidelines in any area of medicine, the NCCN Guidelines® are developed through an explicit review of the evidence integrated with expert medical judgment and recommendations by multidisciplinary panels from NCCN Member Institutions.

For more information about NCCN, the NCCN Member Institutions, and the NCCN Guidelines, visit NCCN.org.

###

About Case Comprehensive Cancer Center

Case Comprehensive Cancer Center is an NCI-designated Comprehensive Cancer Center located at Case Western Reserve University. The center, which has been continuously funded since 1987, integrates the cancer research activities of the largest biomedical research and health care institutions in Ohio – Case Western Reserve, University Hospitals (UH) Case Medical Center and the Cleveland Clinic. NCI-designated cancer centers are characterized by scientific excellence and the capability to integrate a diversity of research approaches to focus on the problem of cancer. It is led by Stanton Gerson, MD, Asa and Patricia Shiverick-Jane Shiverick (Tripp) Professor of Hematological Oncology, director of the National Center for Regenerative Medicine, Case Western Reserve, and director of the Seidman Cancer Center at UH Case Medical Center.

About University Hospitals

University Hospitals, the second largest employer in Northeast Ohio with 25,000 employees, serves the needs of patients through an integrated network of 15 hospitals, 29 outpatient health centers and primary care physician offices in 15 counties. At the core of our $3.5 billion health system is University Hospitals Case Medical Center, ranked among America’s 50 best hospitals by U.S. News & World Report in all 12 methodology-ranked specialties. The primary affiliate of Case Western Reserve University School of Medicine, UH Case Medical Center is home to some of the most prestigious clinical and research centers of excellence in the nation, including cancer, pediatrics, women's health, orthopaedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health, transplantation and genetics. Its main campus includes UH Rainbow Babies & Children's Hospital, ranked among the top children’s hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University. For more information, go to www.uhhospitals.org

About Cleveland Clinic

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. More than 3,000 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. The Cleveland Clinic health system includes a main campus near downtown Cleveland, eight community hospitals, more than 75 Northern Ohio outpatient locations, including 16 full-service Family Health Centers, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and, scheduled to begin seeing patients in 2015, Cleveland Clinic Abu Dhabi. In 2013, there were 5.5 million outpatient visits throughout the Cleveland Clinic health system and 157,000 hospital admissions. Patients came for treatment from every state and from more than 130 countries. Visit us at www.clevelandclinic.org.  Follow us at www.twitter.com/ClevelandClinic.

About Taussig Cancer Institute

The Taussig Cancer Institute provides world-class cancer care enhanced by innovative basic, genetic and translational research. It offers the most effective techniques to achieve long-term survival and quality of life. The Taussig Cancer Institute’s more than 250 specialists care for approximately 30,000 patients a year, with access to a wide range of clinical trials. The Taussig Cancer Institute is one of 27 institutes at Cleveland Clinic, a nonprofit academic medical center ranked among the nation’s top hospitals (U.S. News & World Report), where more than 3,000 physicians and researchers in 120 specialties collaborate to give every patient the best outcome and experience.clevelandclinic.org/cancer

 

>View Article<



January 1, 2015
Bad Luck of Random Mutations Plays Predominant Role in Cancer, Study Shows

Scientists from the Johns Hopkins Kimmel Cancer Center have created a statistical model that measures the proportion of cancer incidence, across many tissue types, caused mainly by random mutations that occur when stem cells divide. By their measure, two-thirds of adult cancer incidence across tissues can be explained primarily by “bad luck,” when these random mutations occur in genes that can drive cancer growth, while the remaining third are due to environmental factors and inherited genes.

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is one of the 25 NCCN Member Institutions.   

>View Article<



December 31, 2014
1.5 Million Lives Spared by Cancer Death Rate Reduction in 20 Years, Study Says

More than 1.5 million lives were spared thanks to a nationwide decrease in cancer deaths in the past 20 years, according to a new report by the American Cancer Society.

This article features commentary from Dr. Michael Neuss, Chief Medical Officer at Vanderbilt-Ingram Cancer Center—one of the 25 NCCN Member Institutions.   

>View Article<



December 30, 2014
Cancer-Causing Mutation Discovered in 1982 Finally Target of Clinical Trials

A recent article in the journal Cancer Discovery describes clinical trials at the University of Colorado Cancer Center and elsewhere that match drugs to this long-overlooked oncogene, offering targeted treatment options for cancers that harbor these gene abnormalities.

University of Colorado Cancer Center is one of the 25 NCCN Member Institutions.  

>View Article<



December 30, 2014
Immunotherapy, Genomic Profiling and Potential Game Changing Drugs Lead List of 2014 Dana-Farber Research Highlights

This press release describes highlights of the Dana-Farber Cancer Institute 2014 cancer research and clinical developments, including work in immunotherapy, genomic profiling, and investigating game-changing drug therapies.

Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center is one of the 25 NCCN Member Institutions.   

>View Article<



December 1, 2014
“Your Odds of Surviving Cancer Depend Very Much on where You Live,” NPR.com

This story features a study published in Lancet that surveyed more than 27 million patients internationally and revealed a huge gulf in cancer survival worldwide.

This story includes commentary from a physician at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance—one of the 25 NCCN Member Institutions.

>View Article<



December 1, 2014
“Breast Cancer Vaccine Shows Promise in Slowing Progress,” TIME.com

An initial safety trial of a breast cancer vaccine has proven safe, with preliminary results suggesting the vaccine will slow cancer progression.

The vaccine, which is being developed by researchers at Washington University School of Medicine in St. Louis, is meant for patients with breast cancers that express a protein found only in breast tissue called mammaglobin-A.

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is one of the 25 NCCN Member Institutions.  

>View Article<



November 26, 2014
“Protein Predicts Response to New Immunotherapy Drug,” Yale Cancer Center/Smilow Cancer Hospital

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

The study, led by a Yale Cancer Center investigator, is described in the November 27 edition of the journal Nature.

Yale Cancer Center and Smilow Cancer Hospital is one of the 25 NCCN Member Institutions. 

>View Article<



November 26, 2014
“Protein Predicts Response to New Immunotherapy Drug,” Yale Cancer Center/Smilow Cancer Hospital

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

The study, led by a Yale Cancer Center investigator, is described in the November 27 edition of the journal Nature.

Yale Cancer Center and Smilow Cancer Hospital is one of the 25 NCCN Member Institutions. 

>View Article<



November 26, 2014
“Research on a Rare Cancer Exposes Possible Route to New Treatments,” Huntsman Cancer Institute at the University of Utah

Researchers from Huntsman Cancer Institute at the University of Utah—one of the 25 NCCN Member Institutions—discovered the unusual role of lactate in the metabolism of alveolar soft part sarcoma (ASPS), a rare, aggressive cancer that primarily affects adolescents and young adults. The study also confirmed that a fusion gene is the cancer-causing agent in this disease. The research results were published online in the journal Cancer Cell on November 26.

>View Article<



November 19, 2014
“Study Shows Link Between Genes, Seaside Vacations & Future Melanoma Risk,” University of Colorado Cancer Center

A longitudinal study established a link between different ultraviolet (UV) exposure measures in children, such as the number of waterside vacations or sunburns, and biomarkers of melanoma risk, such as the number of freckles or moles that develop during childhood, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

This story features commentary from an investigator at University of Colorado Cancer Center—one of the 25 NCCN Member Institutions.

>View Article<



November 19, 2014
“Power behind ‘Master’ Gene for Cancer Discovered,” The University of Texas MD Anderson Cancer Center

A study at The University of Texas MD Anderson Cancer Center led by Mong-Hong Lee, Ph.D., a professor of molecular and cellular oncology, has demonstrated the significance of CSN6 in regulating Myc, which may very well open up a new pathway for treating and killing tumors. The study results are published in this month’s issue of Nature Communications.

The University of Texas MD Anderson Cancer Center is one of the 25 NCCN Member Institutions.   

>View Article<



November 19, 2014
“Moffitt Cancer Center Researchers Use Evolutionary Principles to Model Cancer Mutations, Discover Potential Therapeutic Targets,” Moffitt Cancer Center

Moffitt Cancer Center researchers are taking a unique approach to understanding and investigating cancer by utilizing evolutionary principles and computational modeling to examine the role of specific genetic mutations in the Darwinian struggle among tumor and normal cells during cancer growth.

Moffitt Cancer Center is one of the 25 NCCN Member Institutions.   

>View Article<



November 17, 2014
“Study Reveals How Some Breast Cancers Become Resistant to Targeted Drugs,” Memorial Sloan Kettering Cancer Center

A team of researchers from Memorial Sloan Kettering and elsewhere has gained new insights into how tumors develop resistance to targeted drugs. The findings suggest that adding additional drugs to the treatment regimen may provide a longer-lasting response and a greater benefit to patients.

Memorial Sloan Kettering Cancer Center is one of the 25 NCCN Member Institutions.  

>View Article<



November 17, 2014
“Potential Therapy Found for Incurable Pediatric Brain Tumor,” Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Northwestern Medicine scientists have discovered a new potential drug therapy for a rare, incurable pediatric brain tumor by targeting a genetic mutation found in children with the cancer.

By inhibiting the tumor-forming consequences of the mutation using an experimental drug called GSKJ4, they delayed tumor growth and prolonged survival in mice with pediatric brainstem glioma.

Robert H. Lurie Comprehensive Cancer Center at Northwestern University is one of the 25 NCCN Member Institutions.  

>View Article<



November 12, 2014
"Gene Sequencing Projects Link Two Mutations to Ewing Sarcoma Subtype with Poor Prognosis," St. Jude Children’s Research Center/The University of Tennessee Health Science Center

An international collaboration has identified frequent mutations in two genes that often occur together in Ewing sarcoma (EWS) and that define a subtype of the cancer associated with reduced survival. The research, conducted by the St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project and the Institut Curie-Inserm through the International Cancer Genome Consortium, appears in the current issue of the scientific journal Cancer Discovery.

St. Jude Children’s Research Center/The University of Tennessee Health Science Center is one of the 25 NCCN Member Institutions. 

>View Article<



November 11, 2014
"Cancer-Killing Virus Plus Chemotherapy Drug Might Treat Recurrent Ovarian Cancer," The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

In six out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and five-year survival is only 27 percent. A new study suggests that a cancer-killing virus combined with a chemotherapy drug might safely and effectively treat advanced or recurrent forms of the disease.

 The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute is one of the 25 NCCN Member Institutions. 

>View Article<



November 11, 2014
"New Test Developed at Dana-Farber/Brigham and Women's Cancer Center Speeds Treatment Decisions for Blood Cancer Patients," Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center

In a major advance in the care of these patients, physicians at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) have begun using Rapid Heme Panel, a high-tech genetic test that provides, within a matter of days, an unprecedented amount of critical information to aid the choice of treatment.

Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center is one of the 25 NCCN Member Institutions. 

>View Article<



November 10, 2014
"MD Anderson’s David M. Gershenson, MD, Receives IGCS’s Award for Excellence in Gynecologic Oncology," The University of Texas MD Anderson Cancer Center

For his myriad clinical, organizational and scientific accomplishments in the field of gynecologic oncology and the health and well-being of women, David M. Gershenson, M.D. has been recognized with the International Gynecology Cancer Society’s (IGCS) Award of Excellence.

The University of Texas MD Anderson Cancer Center is one of the 25 NCCN Member Institutions. 

>View Article<



November 10, 2014
"Promising Prognostic Biomarker Candidates for Ovarian Cancer Uncovered by Roswell Park Team," Roswell Park Cancer Institute

Cancer researchers at Roswell Park Cancer Institute (RPCI) have identified two independent classes of novel candidate prognostic markers for ovarian cancer, advancing efforts to develop targeted therapies for the disease. The findings resulted from two separate studies published in the peer-reviewed journal PLoS ONE and based on data from The Cancer Genome Atlas (TCGA), the world’s largest public database on gene expression in different tumor types.

Roswell Park Cancer Institute is one of the 25 NCCN Member Institutions. 

>View Article<



November 10, 2014
"Colorectal Cancer Rates Increasing for U.S. Adults Under 50," Oncology Nurse Advisor

While rates of colorectal cancer (CRC) have fallen among older Americans, cases among adults aged 20 to 49 are rising and expected to continue to do so, according to research from The University of Texas MD Anderson Cancer Center published online Nov. 5 in JAMA Surgery.

The University of Texas MD Anderson Cancer Center is one of the 25 NCCN Member Institutions. 

>View Article<



November 10, 2014
"Mayo Clinic Researchers Identify First Steps in Formation of Pancreatic Cancer," Mayo Clinic Cancer Center

Researchers at Mayo Clinic’s campus in Jacksonville say they have identified first steps in the origin of pancreatic cancer and that their findings suggest preventive strategies to explore.

Mayo Clinic Cancer Center is one of the 25 NCCN Member Institutions. 

>View Article<



November 9, 2014
"As U.S. Cases of Skin Cancer Rise, Costs Skyrocket, Too," Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Rising rates of skin cancer in the U.S. are taking a toll not only on the nation’s health, but on its wallet as well, a new federal study finds.

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance is one of the 25 NCCN Member Institutions.

>View Article<



November 9, 2014
"Yale Study: Medicare Costs for Breast Cancer Screenings Soar, but Benefits Remain Unclear," New Hampshire Register

The cost of Medicare-funded breast cancer screenings jumped 44 percent from $666 million to $962 million from 2001 to 2009, yet those added millions did not improve early detection rates among the 65 and older Medicare population, according to a Yale School of Medicine study published recently in the Journal of the National Cancer Institute.

Yale Cancer Center/Smilow Cancer Hospital is one of the 25 NCCN Member Institutions. 

>View Article<



November 7, 2014
"Researchers Take New Approach to Stop 'Most Wanted' Cancer Protein," Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center

Researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have found a way to defeat one of the most tantalizing yet elusive target proteins in cancer cells – employing a strategy that turns the protein’s own molecular machinations against it.

Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center is one of the 25 NCCN Member Institutions. 

>View Article<



November 6, 2014
"Dr. Candace Johnson Named Cancer Center Director at Roswell Park Cancer Institute," Roswell Park Cancer Institute

Candace S. Johnson, PhD, has been promoted to Cancer Center Director at Roswell Park Cancer Institute (RPCI), the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. In this new role with the Institute, she will manage the Institute’s Cancer Center Support Grant (CCSG) from the NCI as Principal Investigator and will oversee faculty recruitment and allocation of resources including space, personnel and institutional funds.

Roswell Park Cancer Institute is one of the 25 NCCN Member Institutions. 

>View Article<